FDA

Research has confirmed chemicals in sunscreen can be detected in the blood of users after just one application. But experts urge people continue using sunscreen as there is no evidence to suggest these findings point to negative health consequences.

Marking an impressive milestone in the development of MDMA-assisted psychotherapy for PTSD, the FDA has approved the treatment for Expanded Access, allowing certain patients access to the therapy before full market approval is granted.

A Phase 3 clinical trial into the efficacy of a fish-oil-derived drug called Epanova has been discontinued. The trial was designed to establish the use of the drug, a formulation of two omega-3 fatty acids, as an adjunct to statins for heart disease.

A promising new cancer drug will soon enter phase 2 clinical trials, after finding success in animal models and preliminary human studies. Known as AMG 510, the drug targets a gene mutation that’s one of the most common causes of cancer.

Continuing the wave of cutting-edge new migraine drugs reaching the American market, the U.S. Food and Drug Administration (FDA) has now approved the first oral calcitonin gene-related peptide (CGRP) antagonist for acute migraine treatment.

After months of concern, the CDC has revealed it's confident in claiming the “vast majority” of recent lung injury cases related to e-cigarette use can be linked to illicit THC vape liquids containing vitamin E acetate.

The FDA has finally approved two new low-nicotine cigarettes for the US market. The announcement comes less than a month after the FDA faced criticism for seemingly backing down on a 2017 initiative to regulate nicotine levels in cigarettes.

The FDA has expanded its approval of a fish oil-derived drug designed to reduce risk of cardiovascular events in adults with elevated triglyceride levels. The drug was initially approved in 2012, but limited to a highly specific sub-set of patients.

In an unusual turn of events a new Alzheimer’s drug, previously declared a failure in March, has been resurrected with the pharmaceutical company behind the treatment suggesting the earlier decision was premature and based on incorrect data analysis.

A new update on the ongoing vaping crisis has revealed nearly 1,500 lung injury cases have been identified, with 33 confirmed deaths. Alongside this news, Juul announced it is suspending sales of four popular e-cigarette flavors pending FDA review.

The first oral immunotherapy agent to treat peanut allergy is set to be approved, but questions still remain over how effective and long-lasting it is.

Amid the e-cigarette health crisis in the US, the Trump administration announced a plan to ban all non-tobacco-flavored e-cigarette products.